trending Market Intelligence /marketintelligence/en/news-insights/trending/1j1r58uchbrqqmml5hfc5q2 content esgSubNav
In This List

CRISPR Therapeutics chief legal officer retires

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


CRISPR Therapeutics chief legal officer retires

Zug, Switzerland-based CRISPR Therapeutics AG said Tyler Dylan-Hyde retired as chief legal officer of the company.

Dylan-Hyde joined the company in January 2015.

The company develops gene-editing therapies for various diseases, including sickle cell disease and hemophilia.